BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
Stock Snapshot
The current BioMarin(BMRN) stock price is $54.90, with a market capitalization of 10.49B. The stock trades at a price-to-earnings (P/E) ratio of 20.45.
As of 2026-01-17, BioMarin(BMRN) stock has fluctuated between $54.58 and $55.22. The current price stands at $54.90, placing the stock +0.6% above today's low and -0.6% off the high.
The BioMarin(BMRN)'s current trading volume is 2.08M, compared to an average daily volume of 2.24M.
During the past year, BioMarin(BMRN) stock moved between $50.76 at its lowest and $73.51 at its peak.
During the past year, BioMarin(BMRN) stock moved between $50.76 at its lowest and $73.51 at its peak.
BMRN News
Earlier this week, BioMarin Pharmaceutical appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new C-level role reporting...
Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium BioMarin’s latest clinical update cent...
Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerfu...
Analyst ratings
74%
of 27 ratingsMore BMRN News
Analyst Yun Zhong of Wedbush maintained a Buy rating on BioMarin Pharmaceutical, retaining the price target of $94.00. Claim 70% Off TipRanks Premium Unlock hed...
William Blair analyst Sami Corwin has maintained their neutral stance on BMRN stock, giving a Hold rating on January 8. Claim 70% Off TipRanks Premium Unlock he...
Phil Nadeau, an analyst from TD Cowen, maintained the Buy rating on BioMarin Pharmaceutical. The associated price target remains the same with $120.00. Claim 70...
BioMarin Pharmaceutical (BMRN) announced it has appointed Arpit Dave as Executive Vice President, Chief Digital and Information Officer, a new position reportin...